Assembly Biosciences Inc (NASDAQ:ASMB) has been given an average rating of “Hold” by the eight analysts that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $52.00.
A number of brokerages have weighed in on ASMB. SVB Leerink restated an “outperform” rating on shares of Assembly Biosciences in a research note on Friday, August 28th. ValuEngine downgraded shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 2nd. BidaskClub cut shares of Assembly Biosciences from a “hold” rating to a “sell” rating in a report on Friday. William Blair reissued a “buy” rating on shares of Assembly Biosciences in a report on Thursday, June 25th. Finally, Zacks Investment Research downgraded shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, June 23rd.
A number of hedge funds have recently added to or reduced their stakes in ASMB. FMR LLC increased its stake in Assembly Biosciences by 0.6% during the first quarter. FMR LLC now owns 445,716 shares of the biopharmaceutical company’s stock valued at $8,776,000 after purchasing an additional 2,680 shares during the last quarter. BlackRock Inc. increased its stake in Assembly Biosciences by 15.6% during the first quarter. BlackRock Inc. now owns 2,297,866 shares of the biopharmaceutical company’s stock valued at $34,079,000 after purchasing an additional 310,648 shares during the last quarter. American International Group Inc. increased its stake in Assembly Biosciences by 16.7% during the first quarter. American International Group Inc. now owns 16,821 shares of the biopharmaceutical company’s stock valued at $249,000 after purchasing an additional 2,410 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. bought a new stake in Assembly Biosciences during the first quarter valued at $194,000. Finally, Aperio Group LLC bought a new stake in Assembly Biosciences during the first quarter valued at $149,000. Hedge funds and other institutional investors own 91.23% of the company’s stock.
Two trading icons unveil the secret to beat Wall Street into the markets. “Since I’ve started… I’m already up $46,500” – A first user.
Shares of NASDAQ ASMB opened at $18.77 on Friday. The stock’s 50-day simple moving average is $22.22 and its 200-day simple moving average is $19.91. The firm has a market capitalization of $616.69 million, a PE ratio of -7.45 and a beta of 1.20. Assembly Biosciences has a fifty-two week low of $8.13 and a fifty-two week high of $27.84. The company has a debt-to-equity ratio of 0.03, a quick ratio of 13.61 and a current ratio of 13.61.
Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $0.19 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.22. Assembly Biosciences had a negative net margin of 136.24% and a negative return on equity of 30.14%. The company had revenue of $39.38 million during the quarter, compared to analysts’ expectations of $30.54 million. On average, sell-side analysts forecast that Assembly Biosciences will post -2.2 earnings per share for the current fiscal year.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.
Recommended Story: What is the return on assets formula?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
10 Video Game Stocks That Will Cause Investors to Jump Off Their Couch
Video games are big business. In 2019, sales of video games were nearly $150 billion worldwide according to the research firm Newzoo. That marked a 7.2% growth from the previous year. And, at the time of the report Newzoo estimated that global video game sales would rise to nearly $160 billion in 2020.
But in the aftermath of the Covid-19 pandemic, things may be changing. The video game industry is undergoing profound changes. Consumers truly have an a la carte model for gaming. Do they want to use a traditional console? They can. How about their laptop? Check. And they can also use their mobile device.
But it’s not just the hardware they use. Multiplayer games are now the rage as is the ability to play online versus other competitors. And then there’s the whole movement towards esports which is helping to inspire a service like Twitch that allows people to watch other people play video games.
As investors, the growth of digital downloads and cloud-based streaming is playing a significant role in the way video game stocks are perceived. And it’s a big reason why many video game stocks are among the best investments at the moment.
In this special presentation, we’ll look at pure-play video game stocks as well as technology companies that are leveraging their strengths to get a share of this growing pie.
View the “10 Video Game Stocks That Will Cause Investors to Jump Off Their Couch”.
